LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

MacroGenics Inc

Fermé

SecteurSoins de santé

1.2 -5.51

Résumé

Variation du prix de l'action

24h

Actuel

Min

1.18

Max

1.28

Chiffres clés

By Trading Economics

Revenu

-26M

-41M

Ventes

-4.5M

13M

P/E

Moyenne du Secteur

38.83

50.291

BPA

-0.65

Marge bénéficiaire

-311.067

Employés

341

EBITDA

-27M

-39M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+274.02% upside

Dividendes

By Dow Jones

Prochains Résultats

4 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-70M

83M

Ouverture précédente

6.71

Clôture précédente

1.2

Sentiment de l'Actualité

By Acuity

50%

50%

162 / 380 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Neutral Evidence

MacroGenics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

27 juin 2025, 20:51 UTC

Résultats

These Stocks Moved the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 juin 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27 juin 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

27 juin 2025, 20:48 UTC

Market Talk

Computer Lobby Cheers Move to Punish Canada Over Digital Tax -- Market Talk

27 juin 2025, 20:46 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

27 juin 2025, 20:46 UTC

Market Talk

Canada Dismissal of Risk From Digital Tax Is 'Shocking' -- Market Talk

27 juin 2025, 19:31 UTC

Market Talk

Canada CEOs Call for Carney to Drop Digital Tax -- Market Talk

27 juin 2025, 19:19 UTC

Market Talk

Oil Posts Weekly Loss As Geopolitical Premium Evaporates -- Market Talk

27 juin 2025, 19:16 UTC

Market Talk

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

27 juin 2025, 18:57 UTC

Acquisitions, Fusions, Rachats

Russian Oligarch Roman Abramovich Is Evraz PLC's Largest Shareholder With 29% Stake -- WSJ

27 juin 2025, 18:57 UTC

Acquisitions, Fusions, Rachats

Evraz North America Parent Evraz PLC Remains Under Sanction by U.K. -- WSJ

27 juin 2025, 18:57 UTC

Acquisitions, Fusions, Rachats

Evraz North America Employs About 3,400 People, Has 3.5 Million Tons of Finished Steel Capacity -- WSJ

27 juin 2025, 18:57 UTC

Acquisitions, Fusions, Rachats

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 juin 2025, 18:57 UTC

Acquisitions, Fusions, Rachats

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 juin 2025, 18:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27 juin 2025, 18:42 UTC

Market Talk

Canada's Carney 'Likely Amenable' to Dropping Digital-Services Tax -- Market Talk

27 juin 2025, 18:39 UTC

Market Talk
Résultats

Nike's Second-Half Prospects Can Get Better as Worst is Behind it -- Market Talk

27 juin 2025, 18:29 UTC

Market Talk

Canada Recession Risks Likely to Rise With Trump's Termination of Tariff Talks -- Market Talk

27 juin 2025, 18:18 UTC

Market Talk

Canadian Dollar Sharply Weakens on Trump's Surprise End to US-Canada Tariff Talks -- Market Talk

27 juin 2025, 18:16 UTC

Market Talk

Trump's Threat Against Canada Weighs Down Treasurys -- Market Talk

27 juin 2025, 17:16 UTC

Market Talk

U.S. Oil Rig Count Falls by 6 to 432 -- Market Talk

27 juin 2025, 17:08 UTC

Résultats

McDonald's Stock Has Slipped. One Analyst Sees 21% Upside. -- Barrons.com

27 juin 2025, 16:52 UTC

Acquisitions, Fusions, Rachats

Nike Stock Soars After Earnings. Is It Time to Just Buy It? -- Barrons.com

27 juin 2025, 16:22 UTC

Résultats

These Stocks Are Moving the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 juin 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

27 juin 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27 juin 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

27 juin 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

27 juin 2025, 15:59 UTC

Market Talk

Gold Futures Slump on Improving Risk Appetite -- Market Talk

27 juin 2025, 15:56 UTC

Market Talk

Nvidia Again Helping To Power New S&P Highs -- Market Talk

Comparaison

Variation de prix

MacroGenics Inc prévision

Objectif de Prix

By TipRanks

274.02% hausse

Prévisions sur 12 Mois

Moyen 4.75 USD  274.02%

Haut 8 USD

Bas 3 USD

Basé sur 6 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

6 ratings

2

Achat

4

Maintien

0

Vente

Score Technique

By Trading Central

1.47 / 1.64Support & Résistance

Court Terme

Neutral Evidence

Moyen Terme

Bullish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

162 / 380Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.